Completed PHASE2 INTERVENTIONAL 2-arm NCT01406873

Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1

A Randomized, Placebo Controlled, Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type-1 (DM1)

Sponsor: University of Rochester

Updated 9 times since 2017 Last updated: May 21, 2018 Started: Jun 30, 2011 Primary completion: Feb 28, 2017 Completion: Mar 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01406873, this PHASE2 trial focuses on Myotonic Dystrophy and remains completed. Sponsored by University of Rochester, it has been updated 9 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jul 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Jul 2018 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed PHASE2
May 2017 — Apr 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Feb 2017 — May 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Rochester

Data source: University of Rochester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States